cbdMD, Inc.

cbdMD, Inc.

YCBD
cbdMD, Inc.US flagNew York Stock Exchange American
0.58
USD
+0.01
- -
6.07MMarket Cap
cbdMD, Inc.
YCBD
(New York Stock Exchange American)

Recent

price

0.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
177.15
215.03
21.35
476.02
341.6
291.48
213.31
95.56
36.14
4.77
2.38
Revenue per Share
- -
-292.68
-83.55
-19.16
-1,014.94
99.79
-170.04
-446.37
-106.57
-14.29
-1.09
-0.37
Basic EPS, GAAP
- -
-263.74
-112.34
-276.96
-334.62
-97.74
-107.7
-94.33
-18.2
-1.19
-0.41
-0.32
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
2.99
16.74
24.11
14.51
- -
- -
- -
Dividend per Share
- -
-391
-300.4
-309.73
-1,199.18
-386.07
-480.19
-888.23
-689.75
-337.74
-44.6
-21.48
Book Value per Share
- -
-67.97
91.71
504.26
-778.91
23.46
153.75
81.85
22.97
-1.73
1.27
0.82
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
8
Basic Weighted Avg Shares
- -
2
4
- -
24
42
44
35
24
19
19
20
Sales/Revenue/Turnover
- -
-183.76
-5.35
77.34
-60.72
-41.98
-44.1
-48.9
-38.37
-17.02
-11.27
-13.4
Operating Margin (%)
- -
- -
- -
- -
- -
2
2
3
3
2
2
2
Depreciation Expense
- -
-3
-2
- -
-50
13
-23
-70
-23
-4
-2
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-165.22
-38.85
-89.76
-213.21
30.09
-52.6
-197.96
-94.96
-18.99
-10.63
-13.29
Profit Margin (%)
1
-1
2
11
12
16
30
11
3
-2
3
5
Working Capital
- -
- -
- -
- -
- -
7
5
4
2
- -
- -
- -
LT Debt
1
- -
5
14
38
79
103
31
9
2
7
9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
10
10
Market Capitalization
3
7
6

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
7
8
8
Cash, Cash Equivalents & STI
2
3
3
Accounts Receivable, Net
1
1
2
Inventories
3
3
3
Total Current Liabilities
3
3
3
Payables & Accruals
2
2
2
ST Debt
1
1
- -
Deferred Revenue
1
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-145.16%
15.85%
268.04%
Free Cash Flow
- -
6.07%
154.59%
Net Income, GAAP
- -
-56.41%
-44.84%
Sales/Revenue/Turnover
- -
-13.37%
-1.5%
Total Cash Common Dividend
- -
- -
-41.7%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
4
5
5
19
2025
5
5
5
5
19
2026
5
6
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.4
-10.84
-1.2
- -
-14.29
2025
-1.73
-1.9
-0.21
- -
-1.09
2026
-0.04
-0.08
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
cbdMD, Inc. (NYSE American: YCBD) produces and distributes cannabidiol (CBD) products throughout the United States. The company owns and operates consumer hemp-based CBD brands including cbdMD, Paw CBD, hempMD, cbdMD Botanicals, Herbal Oasis and ATRx Labs; cbdMD brand offerings comprise CBD tinctures, gummies, topicals, capsules, drink mixes, ready-to-drink cans, sleep aids, focus aids and calming aids, while Paw CBD provides veterinarian-formulated pet products such as tinctures, chews and topicals, and ATRx features functional mushroom supplements. Founded in 2014 and headquartered in Charlotte, North Carolina, cbdMD focuses on health and wellness solutions for humans and pets through e-commerce, third-party retailers and distributors. In September 2025, cbdMD closed a $1.7 million Series B convertible preferred stock private placement with institutional investors including C/M Capital Master Fund, LP, generating net proceeds of approximately $1.5 million to bolster its balance sheet, support working capital needs and pursue growth in its consumer brands.

Company News

APIChatGPT
  • cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina

  • cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation

  • cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination

  • Oasis Launches Hemp-Derived Mixer

  • cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products

  • cbdMD Appoints Wade Brown Chief Marketing Officer

  • cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript

  • cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum

  • cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results

  • cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

  • cbdMD, Inc. (YCBD) Q1 2026 Earnings Call Transcript

  • cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

  • cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

  • Herbal Oasis de cbdMD se expande a Luisiana con Morales Beverage Group después de su fuerte impulso en Texas

  • cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum

  • cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways

  • cbdMD Announces Strategic Acquisition of Bluebird Botanicals

  • Stock Market Today: S&P 500, Nasdaq 100 Futures Climb At The Start Of Christmas Week— Kemper, Trump Media & Technology, cbdMD In Focus

  • Comfort Systems, cbdMD And 3 Stocks To Watch Heading Into Monday

  • cbdMD, Inc. (YCBD) Q4 2025 Earnings Call Transcript